Document:

<PAGE>

                                                                    EXHIBIT 4.11

                              SUBCRIPTION AGREEMENT

PARTY A:          STEPHEN S. CHEN ON BEHALF OF
                  STRONG INTERNATIONAL ENTERPRISES (HK) COMPANY LTD.

PARTY B:          BRADLEY D. EDSON ON BEHALF OF
                  VITAL LIVING INC. (REFERRED TO HEREIN AS THE "COMPANY")

STEPHEN S. CHEN ON BEHALF OF STRONG INTERNATIONAL ENTERPRISES (HK) COMPANY LTD.
AND BRADLEY D. EDSON ON BEHALF OF VITAL LIVING INC. REACHED COMPLETE AGREEMENT
ON THE FOLLOWING TERMS CONCERNING THAT STRONG INTERNATIONAL ENTERPRISES (HK)
COMPANY LTD. PURCHASING STOCKS OF VITAL LIVING INC. ON THE TERMS MUTUALLY AGREED
UPON BY STRONG INTERNATIONAL ENTERPRISES (HK) COMPANY LTD. AND VITAL LIVING INC.

    1.   Strong International Enterprises (HK) Company Ltd. (officially
         registered in Hong Kong, hereinafter referred to as "Strong Company" or
         "Subscriber") will be the entity to purchase between one million and
         five million shares of the Common Stock of Vital Living, Inc. at
         USD1.00/share in accordance with the following terms mutually agreed
         upon by Party A and Party B.

         UNITS OFFERED:             50 Units, at a price per Unit of $100,000.
                                    Each Unit consists of 100,000 shares of
                                    Series B Preferred Stock, 100,000 Class D
                                    Warrants and 100,000 Class E Warrants.
                                    Subscriptions for partial units may be
                                    accepted under certain circumstances.

         OFFERING SIZE-MINIMUM      10 Units or $ 1,000,000

         OFFERING SIZE-MAXIMUM      50 Units or $ 5,000,000

         PREFERRED STOCK            The shares of Preferred Stock included in
                                    the Units are offered at a price of $1.00
                                    per share, convertible into common stock
                                    twelve (12) months from the date of issuance
                                    on a one for one basis.

         DIVIDEND ON PREFERRED:     The Preferred Stock will have a minimum
                                    dividend of 25%, payable in common stock 12
                                    months from the date of its issuance to the
                                    investor. In the event the Common Stock
                                    trades for less than 75 cents per share at
                                    the time the last unit is subscribed for,
                                    all Preferred Stock will increase the
                                    dividend amount to equal the difference
                                    between the trading price and $.75. For
                                    example, if the closing price of the Common
                                    Stock was $.65 cents at the time of the last
                                    investment under this document, the dividend
                                    on the preferred would be increase to 35%
                                    from 25%.

                                                                               1

<PAGE>

         WARRANTS EXERCISE PRICE:

                          -         Class D Warrants: $1.30 per share of Common
                                    Stock.

                          -         Class E Warrants: $1.60 per share of Common
                                    Stock.

         WARRANT TERM:

                  The period commencing on the Initial Closing of the Offering
                  and terminating on the fifth anniversary of such date.

         NUMBER OF SHARES ISSUABLE UPON THE EXERCISE OF EACH OF THE CLASS D
         AND CLASS E WARRANTS:

                  One Share of Common Stock per Warrant

3.       PAYMENT

         In order to complete your subscription, you will be required to
accompany the entire executed Subscription Agreement with the tender of the
correct purchase price in cash, certified check (made payable to Vital Living,
Inc, wire transfer or similar payment. Wire transfers should be sent to WELLS
FARGO BANK, ARIZONA, N.A., ACCOUNT NO. 1014446528 ABA NUMBER 091000019__.,
(SWIFT CODE FOR OVERSEES TRANSFERS IS WFBiUS6S. The minimum investment is one
Unit at $100,000 per Unit although partial Units may be subscribed for in the
sole discretion of the Company. See Paragraph 4 to the Subscription Agreement.

         Deliver or mail items 1, 2 and 3 to the Company at the address on the
previous page.

    1.   Unless fully executed by June 30, 2003, (unless such date is extended
at the sole discretion of the Company for an additional ninety (90) days) this
agreement shall have no effect.

    2.   After Strong Company acquires Vital Living Class B Preferred Stock (as
         described in the Term Sheet (at $1.00/share), Warrants Class D (at
         $1.30/share), Warrants Class E (at $1.60/share), and hold them for one
         year from the date of their issuance, Stephen S. Chen (Chairman & CEO
         of Strong Company) has the full authority to assign any amount of Vital
         Living stocks, Warrants Class D, and Warrants Class E to any companies
         and individuals as Stephen S. Chen chooses.

    3.   Vital Living Inc. will offer free services in helping Stephen S. Chen
         (on behalf of Strong Company) and any other companies and individuals
         as Stephen S. Chen chooses to assign any amount of aforesaid Vital
         Living stocks, Warrants Class D, and Warrants Class E to (hereinafter
         referred to as (Vital Living stockholders, Vital Living warrant
         holders) to sell their Vital Living Stocks and exercise their Vital
         Living Warrants after these stocks and warrants are held for one year
         from the date of their issuance. If there are any legal and finance
         fees in connection with the exercise of the warrants, Vital Living
         agreed to assume those costs.

                                                                               2

<PAGE>

    4.   The Vital Living stockholders shall be responsible for any finance fees
         related to their selling of their Vital Living stocks.

    5.   Strong Company understands and agrees that an investment in the Units
         is not a liquid investment. In particular and in addition to the
         representations in Section 4 hereof, the undersigned recognizes,
         acknowledges and agrees that:

                  5.1      Strong Company must bear the economic risk of
         investment in the Units for an indefinite period of time, since the
         Units have not been registered under the Securities Act of 1933, as
         amended (the "Securities Act") or applicable state securities laws
         ("State Acts"), and, therefore, cannot be transferred or sold unless
         either they are subsequently registered under the Securities Act and
         applicable State Acts, or an exemption from registration is available
         and a favorable opinion of counsel to that effect is obtained. The
         undersigned acknowledges and agrees that the Company has no independent
         obligation to file with the Securities and Exchange Commission ("SEC")
         relating to the units or any securities included therewith. Pursuant to
         Rule 144, as presently promulgated under the rules of the SEC,
         Subscriber may begin to sell the shares of Common Stock acquired
         hereunder pursuant to the terms of such Rule, as well as, subject to
         applicable holding periods which begin upon the exercise of the
         Warrants, any shares of Common Stock acquired upon the exercise of the
         Warrants.

                  5.2      No market currently exists for any of the Company's
         securities other than its Common Stock and no market for the Units, the
         Series B Preferred Stock, Series D Warrants or the Series E Warrants is
         expected to develop in the foreseeable future.

    6.   In connection with the agreement to purchase Units by Strong Company
         herein, the Company hereby represents and warrants as follows:

                  6.1      The Company is a corporation duly organized and
         validly existing and in good standing under the laws of the State of
         Nevada and has all the requisite power and authority to conduct its
         business and own and operate its properties, and to enter into and
         execute this Agreement and to carry out the transactions contemplated
         hereby.

                  6.2      The Company has the power to execute, deliver and
         perform the terms and provisions of this Agreement and has taken all
         necessary action to authorize the execution, delivery and performance
         of this Subscription Agreement, and to authorize the issuance and sale
         of the Units (consisting of the Shares) contemplated by this Agreement,
         and the representatives of the Company executing this Subscription and
         Purchase Agreement are duly authorized to do so.

                  6.3      Assuming the due execution and delivery of this
         Agreement by Strong Company, this Agreement is a legal, valid and
         binding obligation of the Company enforceable in accordance with its
         terms except (a) as its obligations may be affected by bankruptcy,
         insolvency, reorganization, moratorium or similar laws, or by equitable
         principles relating to or limiting creditors' rights generally and (b)
         that the remedies of specific performance, injunction and other forms
         of equitable relief are subject to certain tests of equity
         jurisdiction, equitable defenses and the discretion of the court before
         which any proceeding therefore may be brought.

                                                                               3

<PAGE>

                  6.4      The execution, delivery and performance of this
         Agreement and the fulfillment of or compliance with the terms and
         provisions hereof, including the issuance and sale of the Units
         (consisting of shares of the Series B Preferred Stock and the Warrants)
         contemplated by this Agreement, are not in contravention of or in
         conflict with any applicable laws or any contract to which the Company
         is a party or by which the Company or any of its properties may be
         bound or affected.

                  6.5      The Company has advised Strong Company that true and
         complete copies of its Annual Report on Form 10-k for the Fiscal Year
         ended December 31, 2001, its Quarterly Report on Form 10-Q for the
         period ended September 30, 2002, and a Preliminary Prospectus (the
         "Preliminary Prospectus") included in a Registration Statement filed on
         Form SB-2 on December 20, 2003, as amended on March 7, 2003, (the "SEC
         Documents") are available on the EDGAR internet site maintained by the
         Securities and Exchange Commission. These documents are incorporated
         herein by this reference, including the Risk Factors set forth in the
         Preliminary Prospectus. The Company has not provided to the Subscriber
         any information that, according to applicable law, rule or regulation,
         should have been disclosed publicly prior to the date hereof by the
         Company, but which has not been so disclosed. As of their respective
         dates, the SEC Documents complied as to form and substance in all
         material respects with the requirements of the Securities Act or the
         Exchange Act, as the case may be, and other federal, state and local
         laws, rules and regulations applicable to such SEC Documents, and none
         of the SEC Documents contained any untrue statement of a material fact
         or omitted to state a material fact required to be stated therein or
         necessary in order to make the statements therein, in light of the
         circumstances under which they were made, not misleading. The financial
         statements of the Company included in the SEC Documents comply as to
         form and substance in all material respects with applicable accounting
         requirements and the published rules and regulations of the SEC or
         other applicable rules and regulations with respect thereto. Such
         financial statements have been prepared in accordance with generally
         accepted accounting principles applied on a consistent basis during the
         periods involved (except (i) as may be otherwise indicated in such
         financial statements or the notes thereto or (ii) in the case of
         unaudited interim statements, to the extent they may include summary
         notes and may be condensed or summary statements) and fairly present in
         all material respects the financial position of the Company as of the
         dates thereof and the results of operations and cash flows for the
         periods then ended (subject, in the case of unaudited statements, to
         normal year-end audit adjustments).

         6.6      The Company will provide, at no additional cost to Strong
         Company, any and all services, including legal fees, associated with
         the lawful transfer or sale of the Common Stock acquired hereby, or the
         exercise of the Warrants and the subsequent transfer or sale of any
         shares of Common Stock acquired upon the exercise of such Warrants.
         Such services and assistance will be provided in an expedited manner.

         7.       Strong Company represents to and agrees with the Company that:

                                                                               4

<PAGE>

         7.1      Strong Company has carefully reviewed and understand the risks
         of and other considerations relating to a purchase of the Units.

         7.2      The undersigned and his purchaser representative(s), if any,
         have been afforded the opportunity to obtain any information necessary
         to verify the accuracy of any representations or information set forth
         in the Memorandum and have had all of their inquiries to the Company
         answered in full, and have been furnished all requested materials
         relating to the Company, the offering and sale of the Units and any
         other matter described in the Memorandum.

         7.3      Neither the undersigned nor his purchaser representative(s),
         if any, have been furnished any offering literature by the Company or
         any of their affiliates, associates or agents, other than the
         Memorandum, the representations contained herein, and the exhibits and
         attachments thereto and hereto.

         7.4      Strong Company is acquiring the Units for which it hereby
         subscribes as principal for its own investment account, and not (1)
         with a view to the resale or distribution of all or any part thereof,
         (2) on behalf of another person who has not made the foregoing
         representation, or (3) in order for any person to acquire less than the
         minimum subscription required hereunder, unless a lesser subscription
         specifically has been accepted by the Company.

         7.5      Strong Company is an accredited investor, as defined in Rule
         501(a) of Regulation D promulgated pursuant to the Securities Act, by
         virtue of the fact that it is an accredited partnership, corporation,
         trust or other entity investors must and at least one of the following
         statements is applicable

                  _____(i) The undersigned is a trust, with total assets in
                  excess of $5,000,000, not formed for the specific purpose of
                  acquiring the securities offered, whose purchase is directed
                  by a sophisticated person as described in Rule 506(b)(2)(ii)
                  of Regulation D or

                  _____(ii) All of the equity owners of the undersigned qualify
                  as an "accredited investor".

         For purposes of determining whether Strong Company is an "accredited
         investor" at least one of the following statements must be applicable:

                  _____(i) The undersigned had individual income (exclusive of
                  any income attributable to spouse) of more than $200,000 in
                  each of the most recent two years or joint income with the
                  undersigned's spouse in excess of $300,000 in each of such
                  years and reasonably expects to have income of at least the
                  same level for the current year.

                  _____(ii) The undersigned has an individual net worth, or a
                  combined net worth with the undersigned's spouse, in excess of
                  $1,000,000. For purposes of

                                                                               5

<PAGE>

                  this Subscription Agreement, "individual net worth" means the
                  excess of total assets at fair market value, including home
                  and personal property, over total liabilities.

         7.6      Strong Company understands the fundamental aspects of and
         risks involved in an investment in the Company as are reflected in the
         Preliminary Prospectus, and that the undersigned has read and reviewed
         each Risk Factor set forth therein and has had an opportunity to
         question management of the Company about its business, prospects and
         financial condition.

         7.7      Strong Company (1) is authorized and otherwise duly qualified
         to purchase and hold the Units, (2) has its principal place of business
         at its residence address set forth on the Subscription Agreement
         Signature Page hereof, (3) has not been formed for the specific purpose
         of acquiring the Units, and (4) has submitted and executed all
         documents required pursuant to the Certificate for Corporate,
         Partnership, Trust and Joint Purchasers and Special Subscription
         Instructions. The person executing this Subscription Agreement and all
         other documents related to the offering hereby represents that he is
         duly authorized to execute and deliver all such documents on behalf of
         the entity. IF THE UNDERSIGNED IS ONE OF THE AFOREMENTIONED ENTITIES,
         IT HEREBY AGREES TO SUPPLY ANY ADDITIONAL WRITTEN INFORMATION THAT MAY
         BE REASONABLY REQUIRED BY THE COMPANY.

         7.8      All of the information that the undersigned has heretofore
         furnished to the Company, or that is set forth herein with respect to
         himself, his financial position, and his business and investment
         experience, is correct and complete as of the date hereof, and, if
         there should be any material change in such information prior to the
         closing of the sale of the Units, the undersigned will immediately
         furnish the revised or corrected information to the Company.

         7.9      Strong Company consents to the placement of a legend on any
         certificate(s) or other document evidencing the Units (including the
         underlying securities), stating that such securities have not been
         registered under the Securities Act and setting forth or referring to
         the restrictions on transferability and sale thereof. The undersigned
         is aware that the Company will make a notation in its appropriate
         records with respect to the restrictions on the transferability of such
         securities. The legend shall be substantially as follows:

         THE SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
         REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE
         SOLD OR OTHERWISE TRANSFERRED UNLESS COMPLIANCE WITH THE REGISTRATION
         PROVISIONS OF SUCH ACT HAS BEEN MADE OR UNLESS AVAILABILITY OF AN
         EXEMPTION FROM SUCH REGISTRATION PROVISIONS HAS BEEN ESTABLISHED OR
         UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933.

                                                                               6

<PAGE>

         7.10     Strong Company understands that the Company will review this
         Subscription Agreement; and it is further agreed that the Company
         reserves the unrestricted right to reject or limit in whole or in part
         any subscription and to close the offer at any time.

         7.11     Strong Company acknowledges that the Company has agreed to pay
         to certain representatives, brokers and finders, a fee of up to 12.5%
         of the gross proceeds raised and an option to acquire 200,000 shares of
         the Company's Common Stock at $1.30 per share.

         7.12     The foregoing representations are true and accurate as of the
         date hereof, shall be true and accurate as of the date of the Closing
         of this offering, and shall survive such Closing. If, in any respect,
         such representations shall not be true and accurate prior to or upon
         the Closing of this offering, the undersigned shall give written notice
         of such fact to the Company, specifying which representations are not
         true and accurate and the reasons therefore, with a copy to his
         purchaser representative(s), if any.

    8.   Confirmed by Party B, foreign Vital Living stockholders and warrant
         holders (including foreign companies and foreign country citizens) will
         not pay any taxes (such as income tax, profit tax... etc.) in the
         United States when they sell their Vital Living stocks and exercise
         their Vital Living warrants.

    9.   Stephen S. Chen or his representative (who will be informed to Vital
         Living Inc. by Stephen Chen's written notice) will coordinate with
         Vital Living Inc. to get the aforesaid services done by Vital Living
         Inc. in a timely manner.

    10.  Bradley D. Edson on behalf of Vital Living Inc. and Stephen Chen on
         behalf of Strong Company will maintain complete confidentiality on all
         the matters, discussions, communications and legal documents related to
         this mission and all aforesaid subjects.

                               VITAL LIVING, INC.
                             SUBSCRIPTION AGREEMENT
                                 SIGNATURE PAGE

         The undersigned hereby subscribes for the number of Units set forth
         below as described in the Term Sheet dated March 24, 2003, issued by
         Vital Living, Inc., a corporation organized under the laws of the State
         of Nevada. The entire Subscription Agreement, of which this is the
         Signature Page, is provided as an Exhibit to the Memorandum.

         1.       Dated:____________________, 2003

         2.       Number of Units:_____________

         3.       Subscription Price ($100,000 per Unit,
                  minimum subscription one Unit):

                                                                               7

<PAGE>

STRONG INTERNATIONAL ENTERPRISES (HK) COMPANY LTD.

_______________________________________________
Taxpayer Identification
Or Social Security Number

_____________________________________________
Mailing Address including
City, State, Zip Code

Subscription for __________ Units accepted as of _____________________, 2003.

VITAL LIVING, INC.

         By:___________________________________
         Bradley Edson, CEO

                                                                               8

<PAGE>

                        SPECIAL SUBSCRIPTION INSTRUCTIONS

                                       FOR

               CORPORATE, PARTNERSHIP, TRUST, AND JOINT PURCHASERS

         If the investor is a corporation, partnership, trust, or other entity
         or joint purchasers, the following additional instructions must be
         followed. INFORMATION ADDITIONAL TO THAT REQUESTED BELOW MAY ALSO BE
         REQUIRED BY THE COMPANY IN SOME CASES.

         I.       AUTHORIZATION. The investor must provide a copy of (a) the
corporation's articles of incorporation, by-laws and authorizing resolution, or
alternatively, a corporate investor may supply a good standing certificate from
the applicable jurisdiction or some other document establishing that the entity
is validly existing and has the authority to invest, (b) the partnership
agreement, or (c) the trust agreement, as applicable.

         II.      SUBSCRIPTION AGREEMENT

                  A.       CORPORATIONS. An authorized officer of the
         corporation must date, sign, and complete the Subscription Agreement
         with information concerning the corporation. The officer should print
         the name of the corporation above his signature, and print his name and
         office below his signature.

                  B.       PARTNERSHIPS. An authorized partner must date, sign,
         and complete the Subscription Agreement with information concerning the
         partnership. The partner should print the name of the partnership above
         his signature, and print his name and the words "general partner" below
         his signature.

                  C.       TRUSTS. In the case of trust, the authorized trustee
         should date, sign, and complete the Subscription Agreement with
         information concerning the trust. The trustee should print the name of
         the trust above his signature, and print his name and the word
         "trustee" below his signature. In addition, an authorized trustee
         should also provide information requested in the Subscription Agreement
         as it pertains to him as an individual.

                  D.       JOINT OWNERSHIP. Except with regard to married
         couples, joint individual or other investors must individually meet the
         investor suitability requirements; in all cases, each must date, sign,
         and complete the Subscription Agreement. Joint investors must state if
         they are purchasing the Units as joint tenants with the right of
         survivorship, tenants in common, or community property, and each must
         execute the Subscription Agreement Signature Page.

                                                                               9

<PAGE>

                               VITAL LIVING, INC.

                     CERTIFICATE FOR CORPORATE, PARTNERSHIP,

                           TRUST, AND JOINT PURCHASERS

                  If the investor is a corporation, partnership, trust, joint
purchaser, or other entity, an authorized officer, partner, or trustee must
complete, date, and sign this Certificate.

                                   CERTIFICATE

The undersigned hereby certifies that:

         a.       The investor has been duly formed and is validly existing and
         has full power and authority to invest in Vital Living, Inc. (the
         "Company"). The investor has not been formed for the purpose of
         investing in the Units.

         b.       The investor's Subscription Agreement has been duly and
         validly authorized, executed, and delivered by the investor and, upon
         acceptance by the Company, will constitute the valid, binding, and
         enforceable obligation of the investor.

Dated:________________, 2003

         Strong International Enterprises (HK) Company Ltd.

         By:____________________________________________

         Name:__________________________________________

         Title:_________________________________________
         (authorized officer, partner or trustee, etc.)

                                                                              10<PAGE>

                                                                   EXHIBIT 10.25

         AGREEMENT made February __, 2003 by and between Vital Living, Inc., a
Nevada corporation, having its executive offices at 5080 North 40th Street,
Phoenix, Arizona 85015 (the "Company") and Healthcare Financial Services, Inc.,
a Nevada corporation having its executive offices 34522 N. Scottsdale Rd. Suite
D-8 #436 Scottsdale, AZ 85262 (the "Representative").

         The parties agree as follows:

         1.       Appointment as exclusive agent.

                  (a) The Company appoints the Representative as its exclusive
Essentum(TM), and Essentum N.P. sales representative to sell the Company's
products, as listed in Exhibit A hereof (the "Products"), in and throughout the
geographical areas (the "Territory") listed in Exhibit B hereof. Representative
and the individual sales agent working for the Representative, as more fully
described herein (such individuals are referred to herein as a "Sales Rep")
shall be responsible for marketing, locating and contacting, including but not
limited to, physicians and health care professionals, distributors, generating
phone calls and correspondence, and traveling to and from prospective clients.
For purposes of this Agreement "prospective clients and vendors" include but are
not limited to physicians, health care professionals and alternative care
practitioners.

                  (b)      The Representative hereby accepts such appointment
and agrees to sell and promote the Products subject to the provisions and
conditions of this Agreement.

                  (c)      Additional products may be added to the Products by
notice from the Company to Representative.

         2.       Territory; other agreements not barred.

                  (a) The Representative recognizes that the Company:

                           (1)      has appointed, or may appoint, other sales
representatives for the representation of the Products in other territories; and

                           (2)      has appointed, or may appoint, other
representatives in the Territory for products of the Company other than the
Products.

                  (b)      Additional areas may be added to the Territories by
the parties' mutual agreement.

         3.       Representative's duties. The Representative shall:

<PAGE>

                  (a)      Use its best efforts to sell and promote the sale of
the Products within the Territory and abide by the Company's policies as they
are communicated to it. Each Sales Rep shall be required to call on a minimum of
25 accounts per week, with the goal of obtaining from each new account a
commitment to prescribe the Products for patients (each such Sale, a "Sale")
serviced by such account. The sales goal is for each Sales Rep to produce,
commencing by the fifth month following the Launch Date (as defined below)
(assuming there has not occurred an earlier termination as herein provided) 300
new sales per month. For clarity sake, this amount in total would be a minimum
of 1,800 new sales per month (the "Benchmark"). Sale is defined as a minimum of
one or more monthly purchases of Essentum(TM) and Essentum N.P.

                  (b)      Representative shall have six Sales Reps devoted to
selling the Products allocated among the Territory as follows: Portland,
Seattle, "Bay Area" California, Orange County, California and Atlanta. Each
Sales Rep shall report to sales manager Javier Ledesma ("Ledesma"), whose
employment by Representative is a condition precedent to this transaction.

                  (c)      Devote such time as may be reasonably necessary for
the purpose of selling or promoting the sale of the Products.

                  (d)      Handle no other products which are competitive with
the Products without the Company's prior written consent and discontinue the
sale of such competitive products when notified by the Company.

                  (e)      Conduct its business in its own name, maintain a
sales office and pay, subject to the terms of this Agreement, its own expenses
and those of its Sales Rep.

                  (f)      Representative will keep Company advised on a weekly
basis (or sooner) by phone, facsimile or letter, as to the progress of the
above-mentioned project and any and all prospects approached. Company shall be
supplied with prospect names, mailing addresses, telephone and facsimile numbers
by Representative immediately upon request by Company or its agent(s).

         4.       Company's duties; pricing.

                  (a) The Company shall not directly quote on the Products to
any customer in the Territory, and shall refer all such inquiries to the
Representative.

                  (b)      With the Company's prior written consent, the
Representative may quote on or attempt to sell the Products outside the
Territory. The Company's consent shall be effective only on a case-by-case
basis, and shall not be interpreted to extend the Representative's rights
hereunder to such geographical areas with respect to the Products unless Exhibit
B is amended in writing.

                  (c)      The Company shall furnish to the Representative upon
request, pricing, delivery, and technical information covering the Company's
products described in Exhibit A as they may relate to the Representative's sales
efforts.

<PAGE>

                  (d)      The Company shall furnish from time to time to the
Representative information concerning the availability of new products or
processes which may be marketable in the Territory. However, such products or
processes shall not be included in this Agreement unless Exhibit A is so
amended.

                  (e)      Representative will receive appropriate credit in
manuals, brochures and other printed material(s) where such credits would
normally be given.

                  (f)      The Company shall quote to the Representative its
current price list..

                  (g)      The Company shall provide, at its own expense, up to
two (2) days of training at the Company's office in Phoenix, Arizona for each
individual sales person, which training shall occur with all Salespersons in
attendance.

                  (h)      The Company will provide samples of the Products as
may be agreed between the Company and Rep.

                  (i)      The Company agrees to pay Representative, on behalf
of Ledesma, the sum of $5,000 per month for the first two months of the
Agreement. In the event the Company does not terminate this agreement at the end
of 60 days (as more fully set forth in Section 11 below), the Company agrees to
increase said payment to $6,000 per month. In the event the Company does not
terminate this agreement at the end of 90 days (as more fully set forth in
Section 11 below), the Company agrees to increase said payment to $6,500 per
month, which shall be the rate for the balance of the Term. If, however, the
Benchmarks are not reached but the Company nevertheless elects not to terminate
this Agreement, the payment shall remain at the rate of $5,000 per month. If,
however at the end of 120 days the Benchmarks have been reached the Company will
pay Ledisma the difference between what he received and $6,500 per month (i.e.,
as if he was earning $6,500 per month from the inception).

         5.       Fees

                  (a)      The Company shall pay the Representative a commission
on sales in accordance with the Company's schedule of commissions, which will
include product pricing, published and distributed quarterly by the Company. In
no event shall the commissions payable to the Representative be (i) deemed owing
prior to the receipt by the Company of the cash amount equal to the indicated
sale or (ii) less than those specified in the commission schedule attached
hereto as Exhibit D, without the Representative's prior written consent.

                  (b)      Representative shall also entitled to seek
reimbursement for reasonable expenses incurred in connection with the services
to be performed pursuant to this Agreement and pursuant to the budget set forth
on Exhibit E; provided however, in no event may the amount sought for
reimbursement exceed the sum of $500 US per month; and provided further
reimbursement shall be subject to the submission of verification of such
expenses in such format (i.e., including original invoices and/or receipts) as
Company may require.

<PAGE>

                  (c)      In the event Representative reaches their benchmark
at the end of 120 days, it will receive a success fee of $20,000. In the event
Representative is not successful by at least 50%, no payment will be due from
the Company. In the event the success is between 50% and 100%, Representative
will receive a pro rata share of $20,000. In the event the success is greater
than 100%, Representative will receive an additional 5% per sale over benchmark.

                  (d)      Each Sales Rep will receive a non-accountable fee of
$1,000 per month for the first two months of the Agreement.

                  (e)      .All commissions are payable 15 days after the close
of each 30 day cycle.

                  (f)      Refunds and exchanges will be evaluated with mutually
agreed upon resolution.

                  (g)      Company agrees to advance representative fixed fees
as defined in 4(i) and 5(d) or the first two months of the contract in advance.

         6.       Quotation Period; Approval of Sales.

                  (a) Each quotation given by the Company to the Representative
shall be valid for a period of 120 days as to price and delivery.

                  (b) All sales shall be in the name of the Company and shall be
subject to the approval of the Company as to the creditworthiness of the
potential buyers indicated therein (which approval shall be indicated by the
Company's execution of each submitted sales agreement and shall not be deemed).
In no event shall any commission be deemed owing unless and until the Company
shall have received payment in full in respect of any approved purchase
hereunder.

         7.       Shipping costs. The Company agrees to the pricing schedule
which includes shipping and handling above individual consumers and dispensing
practices as attached Exhibit F.

         8.       Trade Secrets - Intellectual Property Rights.

                  (a)      Confidential Information. Representative agrees
during the term of this Agreement and for two (2) years following thereafter to
take all steps reasonably necessary to hold Company's Confidential Information
in trust and confidence. "Confidential Information" includes, but is not limited
to, technical and business information relating to Company's inventions or
products, research and development, production, manufacturing and engineering
processes, costs, profit or margin information, employee skills and salaries,
finances, customers, marketing and production and future business plans, and any
third party's proprietary or confidential information disclosed to
Representative in the course of providing services to Company. Notwithstanding
the other provisions of this Agreement, nothing received by

<PAGE>

Representative will be considered to be Confidential Information if (1) it has
been published or is otherwise readily available to the public other than by a
breach of this Agreement; (2) it has been rightfully received by Representative
from a third party without confidential limitations; (3) it has been
independently developed for Representative by personnel or agents having no
access to the Company Confidential Information; or (4) it was known to
Representative prior to its first receipt from Company.

                  (b)      No Conflict of Interest. Representative warrants that
to the best of its knowledge, there is no other existing contract or duty on
Representative's part inconsistent with this Agreement, unless a copy of such
contract or a description of such duty is attached to this Agreement as Exhibit
B. Representative further agrees not to disclose to Company, or bring onto
Company's premises, or induce Company to use any confidential information that
belongs to anyone other than Company or Representative.

                  (c)      Disclosure of Work Product. As used in this
Agreement, the term "Work Product" means any new or useful discover, improvement
or invention whether or not patentable, and all related know-how, trademarks,
formulae, processes, marketing techniques, trade secrets, ideas, artwork,
software or other copyrightable or patentable works. Representative agrees to
disclose promptly in writing to Company or any person designated by Company, all
Work Product which is solely or jointly conceived, made reduced to practice, or
learned by Representative in the course of any work performed for Company.

                  (d)      Assignment of Representative Work Product.
Representative irrevocably assigns to Company all right, title and interest
worldwide in and to the Company Work Product and all applicable intellectual
property rights related to the Company Work Product, including without
limitation, copyrights, trademarks, trade secrets, patents, moral rights,
contract and licensing rights (the "Intellectual Property Rights").
Representative retains no rights to use the Company's Work Product and agrees
not to challenge the validity of Company's ownership in the Company's Work
Product.

                  (e)      Waiver of Assignment of Other Rights. If
Representative has any rights to the Company Work Product that cannot be
assigned to Company, Representative unconditionally and irrevocably waives the
enforcement of such rights, and all claims and causes of action of any kind
against Company with respect to such rights, and agrees, at Company's request
and expense, to consent to and join in any action to enforce such rights. If
Representative has any right to the Company Work Product that cannot be assigned
to Company or waived by Representative, Representative unconditionally and
irrevocably grants to Company during the term of such rights, an exclusive,
irrevocable, perpetual, world wide, full paid and royalty-fee license, with
rights to sublicense through multiple levels of sublicensees, to reproduce,
create derivative works of, distribute, publicly perform and publicly display by
all means now known or later developed, such rights.

                  (f)      Assistance. Representative agrees to cooperate with
Company or its designee(s), both during and after the term of this Agreement, in
the procurement and maintenance of Company's rights in Company Work Product and
to execute, when requested

<PAGE>

any other documents deemed necessary by Company to carry out the purpose of this
Agreement. Representative agrees to execute upon Company's request, a signed
transfer of copyright to Company in the form attached to this Agreement as
Exhibit E for all Company Work Product subject to copyright protection,
including, without limitation, computer programs, notes, sketches, drawings and
reports. In the event that Company is unable for any reason to secure
Representative's signature to any document required to apply for or execute any
patent, copyright, contract or other application with respect to any Company
Work Product (including improvements, renewals, extensions, continuations,
divisions or continuations in part thereof), Representative hereby irrevocably
designates and appoints Company and its duly authorized officers and agents as
its agents and attorneys in fact to act for and in its behalf and instead of
Representative, to execute and file any such application and to do all other
lawfully permitted acts to further the prosecution and issuance of patents,
copyrights, contracts or other rights thereon with the same legal force and
effect as if executed by Representative.

                  (g)      Return of Company Property. Upon termination of this
Agreement for any reason or in any manner, or at any earlier time upon Company's
request, Representative agrees to promptly deliver all Company property,
including but not limited to all tangible embodiments of the Company Work
Product, and all copies of Company property in Representative's possession to
Company.

         9.       What did this mean?  Moved last change to 5(e)

10.      Termination.

                  (a)      The initial test shall be for sixty (60) days from
the Launch Date . It is anticipated that the Launch Date shall be March 24th,
2003, which date may be modified by a written amendment by the parties. This
agreement may be terminated by the Company, in its sole and absolute discretion.
if, (i) 60 days after the Launch Date, the aggregate result of all of the Sales
Reps is not at 60% of the Benchmark or (ii) 90 days after the Launch Date, the
aggregate result of all of the Sales Reps is not at 80% of the Benchmark. In the
event these levels are not reached, the Company, in its sole and absolute
discretion, may also elect to terminate a partial termination of the Agreement
such that the Company may elect to maintain one of more of the areas of cities
comprising the Territory, but terminating the Company as to other cities or
areas, Exhibit G.

                  (b)      This Agreement shall be for a period of 120 days,
unless extended, in writing, by the parties hereto.

                  (c)      This Agreement may be terminated by the Company at
any time Ledesma is no longer employed by the Representative.

         11.      Consequences of termination. Upon termination:

                  (a)      The Representative shall be entitled to commissions
on all orders received by the Company prior to the expiration of the Agreement,
regardless of time of shipment.

<PAGE>

Within 15 days after the expiration of this Agreement, the Representative shall
give to the Company a list of all outstanding quotations made by the
Representative on the Company's products. The Company shall deliver all orders
which may result from the quotations cited above, provided that it receives such
orders within the validity periods of the respective quotations or any
extensions thereof. The Representative shall be entitled to commissions on such
orders as well.

                  (b)      All catalogs, samples and price lists issued by the
Company and in the possession of the Representative shall be promptly returned
to the Company. All other records pertaining to prices, quotations,
specifications and customers shall be treated as if they were the Company's
confidential property.

                  (c)      During and for a period of two (2) years immediately
following termination of this Agreement by either party, Representative agrees
not to solicit or induce any employee or independent contractor or consultant to
terminate or breach an employment, contractual or other relationship with
Company.

         12.      No employment contract. Nothing contained in the Agreement
shall be construed to constitute the Representative as a partner, employee, or
agent of the Company, nor shall either party have any authority to bind the
other in any respect, it being intended that each shall remain an independent
contractor responsible for his own actions.

         13.      Entire contract. This Agreement contains the entire
understanding of the parties and supersedes all previous verbal and written
agreements. There are no other agreements, representations or warranties not set
forth herein.

         14.      Notices. All notices or other documents under this Agreement
shall be in writing and delivered personally or mailed by certified mail,
postage prepaid, addressed to the Company or the Representative at their last
known addresses.

         15.      Non-waiver. No delay or failure by either party to exercise
any right under this Agreement, and no partial or single exercise of that right,
shall constitute a waiver of that or any other right, unless otherwise expressly
provided herein.

         16.      Headings. Headings in this Agreement are for convenience only
and shall not be used to interpret or construe its provisions.

         17.      Governing law. This Agreement shall be construed in accordance
with and governed by the laws of the State of Arizona.

         18.      Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which
together shall constitute one and the same instrument.

<PAGE>

         19.      Binding effect. The provisions of this Agreement shall be
binding upon and inure to the benefit of each of the parties and their
respective successors and assigns.

         20.      Arbitration. Other than a lawsuit seeking injunctive relief as
provided for in Section 21, all disputes relating to commissions in an amount in
excess of $5,000 shall be arbitrated in the following manner: The party desiring
the arbitration shall give written notice to the other party, naming an
arbitrator and requesting that the party to whom the notice is addressed name an
arbitrator within ten days. The two so selected shall select a third, and the
decision of any two of the three shall be binding upon the parties hereto.
Should either party fail to appoint an arbitrator within the ten-day period, or
if the two selected are unable to agree upon the third arbitrator within the
period of ten days next succeeding their appointment, the selection of the
additional arbitrator shall be made by the then acting president of Judicial
Arbitrations & Mediations, Inc. (JAMS), Phoenix, Arizona.

         21.      Injunctive Relief. A breach of any of the promises or
agreements contained in this Agreement may result in irreparable and continuing
damage to Company for which there may be no adequate remedy at law, and Company
is therefore entitled to seek injunctive relief as well as such other and
further relief as may be appropriate.

         22.      Indemnification and Contribution

         (a)      INDEMNIFICATION BY THE COMPANY. The Company shall indemnify
and hold harmless Representative, and each of their respective officers and
directors and each person who controls the Representative (each such person
being sometimes hereinafter referred to as an "REPRESENTATIVE INDEMNIFIED
PERSON") from and against any losses, claims, damages or liabilities, joint or
several, to which such Representative Indemnified Person may become subject as a
result of any breach of any representation or covenant contained herein; and the
Company hereby agrees to reimburse such Representative Indemnified Person for
all reasonable legal and other expenses incurred by them in connection with
investigating or defending any such action or claim as and when such expenses
are incurred;

         (b)      INDEMNIFICATION BY REPRESENTATIVE. Representative shall
indemnify and hold harmless the Company, and each of their respective officers
and directors and each person who controls the Representative (each such person
being sometimes hereinafter referred to as an "COMPANY INDEMNIFIED PERSON") from
and against any losses, claims, damages or liabilities, joint or several, to
which such Company Indemnified Person may become subject as a result of any
breach of any representation or covenant contained herein; and Representative
hereby agrees to reimburse such Company Indemnified Person for all reasonable
legal and other expenses incurred by them in connection with investigating or
defending any such action or claim as and when such expenses are incurred

         (c)      NOTICE OF CLAIMS, ETC. Promptly after receipt by a party
seeking indemnification pursuant to this Section 22 eithet the Company
Identified Person or the Representative Indemnified Person (each being referred
to herein as an "INDEMNIFIED PARTY") of written notice of any investigation,
claim, proceeding or other action in respect of which indemnification is

<PAGE>

being sought (each, a "CLAIM"), the Indemnified Party promptly shall notify the
party against whom indemnification pursuant to this Section 22 is being sought
(the "INDEMNIFYING PARTY") of the commencement thereof; but the omission to so
notify the Indemnifying Party shall not relieve it from any liability that it
otherwise may have to the Indemnified Party, except to the extent that the
Indemnifying Party is materially prejudiced and forfeits substantive rights and
defenses by reason of such failure. In connection with any Claim as to which
both the Indemnifying Party and the Indemnified Party are parties, the
Indemnifying Party shall be entitled to assume the defense thereof.
Notwithstanding the assumption of the defense of any Claim by the Indemnifying
Party, the Indemnified Party shall have the right to employ separate legal
counsel and to participate in the defense of such Claim, and the Indemnifying
Party shall bear the reasonable fees, out-of-pocket costs and expenses of such
separate legal counsel to the Indemnified Party if (and only if): (x) the
Indemnifying Party shall have agreed to pay such fees, costs and expenses, (y)
the Indemnified Party and the Indemnifying Party shall reasonably have concluded
that representation of the Indemnified Party by the Indemnifying Party by the
same legal counsel would not be appropriate due to actual or, as reasonably
determined by legal counsel to the Indemnified Party, potentially differing
interests between such parties in the conduct of the defense of such Claim, or
if there may be legal defenses available to the Indemnified Party that are in
addition to or disparate from those available to the Indemnifying Party, or (z)
the Indemnifying Party shall have failed to employ legal counsel reasonably
satisfactory to the Indemnified Party within a reasonable period of time after
notice of the commencement of such Claim. If the Indemnified Party employs
separate legal counsel in circumstances other than as described in clauses (x),
(y) or (z) above, the fees, costs and expenses of such legal counsel shall be
borne exclusively by the Indemnified Party. Except as provided above, the
Indemnifying Party shall not, in connection with any Claim in the same
jurisdiction, be liable for the fees and expenses of more than one firm of
counsel for the Indemnified Party (together with appropriate local counsel). The
Indemnified Party shall not, without the prior written consent of the
Indemnifying Party (which consent shall not unreasonably be withheld), settle or
compromise any Claim or consent to the entry of any judgment that does not
include an unconditional release of the Indemnifying Party from all liabilities
with respect to such Claim or judgment.

         23.      Company will add Representation as an additional insured on
all product liability coverage.

         IN WITNESS WHEREOF, this Agreement has been executed as of the date
first above written.

                                    VITAL LIVING INC.

                                    By:_____________________
                                       Stuart Benson

<PAGE>

                                    HEALTHCARE FINANCIAL SERVICES, INC.

                                    By: ___________________________

<PAGE>

                          EXHIBIT "COMMISSION SCHEDULE"

I.  MODELS

         A. MEDICAL RX MODEL

                  1. THE COMPANY SHALL PAY A COMMISSION OF 15% ON SALES AS
                  DEFINED IN 3(a). SCHEDULE OF PAYMENT IS AS FOLLOWS:

                                    1ST 30-DAY ORDER = 15%
                                    2ND 30-DAY ORDER =  0%
                     3RD 30-DAY ORDER = 15% OF 2ND AND 3RD 30-DAY ORDER

                  2. THE COMPANY SHALL PAY A COMMISSION ON SALES GENERATED BY A
                  DISPENSING PRACTITIONER. A "DISPENSING PRACTITIONER" SHALL BE
                  DEFINED AS THOSE PHYSICIAN OFFICES, AND/OR HEALTHCARE CLINICS
                  THAT AGREE TO PURCHASE THE PRODUCT(S) AT A DISCOUNT PRICE, AND
                  THEN SELL THE PRODUCT(S) DIRECT TO THEIR PATIENTS (CUSTOMERS).
                  THE COMMISSION SCHEDULE FOR THE REP THAT PROCURES A
                  "DISPENSING ACCOUNT", IS AS FOLLOWS:

                           a) A BASELINE OF SALES WILL BE ESTABLISHED FOR A FOUR
                           (4) WEEK PERIOD. DURING THIS PERIOD ANY AND ALL
                           PRODUCT(S) SALES WILL BE COMMISSIONED AT A 15% RATE
                           OF PURCHASE PRICE.

                           b) ONCE A BASELINE IS ESTABLISHED FOR THE DISPENSING
                           ACCOUNT, COMMISSIONS WILL BE PAID ON ANY AND ALL
                           PRODUCT(S) PURCHASED BY THE "DISPENSING ACCOUNT",
                           ABOVE AND BEYOND THE ESTABLISHED BASELINE AT AN 8%
                           RATE OF PURCHASE PRICE.

II. PRICING

         A. MEDICAL MODEL

                  1.       ESSENTUM          $ 49.95

                  2.       ESSENTUM NP       $ 49.95

         B. DISPENSING MODEL

                  1.       WHOLESALE

                             a)     ESSENTUM              $ 30.00

                             b)     ESSENTUM NP           $ 30.00

                  2.       WHOLESALE WITH VOLUME DISCOUNT

                             a)     ESSENTUM              $ 30.00

                             b)     ESSENTUM NP           $ 30.00

<PAGE>

                              EXHIBIT "BENCHMARKS"

<TABLE>
<CAPTION>
TIMEFRAME            C/O ATTAINMENT            #SALES
<S>                  <C>                       <C>
 30 DAYS                   30%                    90

 60 DAYS                   60%                   180

 90 DAYS                   80%                   240

120 DAYS                  100%                   300
</TABLE>

<PAGE>

                               EXHIBIT E- EXPENSES

SALES REPRESENTATIVES

Limit

-    $1500 per sales representative to cover the entire 120day launch

-    Where rep anticipates spending more than $375 in any given 30 day period,
     such expense requires pre-approval from J. Ledesma.

-    Any expense over $500 in any 30 day period requires approval from E.VP
     approval.

Expenses covered

-    Meals and entertainment of customers.

-    Professional Relations - gifts (under $25 value) or services (e.g. special
     printing) offered to customers/accounts

Requirements -

-    All expenses must be submitted to J. Ledesma for approval within 3 days of
     close of period.

-    Expense reports will be submitted on standard format provided to each
     representative and will be submitted as hard copy originals with receipts.
     Photocopies must be retained by representatives for personal records.

-    No expense will be accepted without a receipt. No `tear off' restaurant
     receipts can be accepted.

-    All meal/entertainment expenses must be detailed on the Expense Report Form
     to include: (1) those in attendance and (2) purpose of meeting.

-    J. Ledesma will submit all reports (approved and unapproved) to J.Freeman
     for final approval within 7 days of close of period. Any expenses remaining
     unapproved will be resolved by J.Ledesma and J.Freeman within 30 days of
     close of period. Any expenses not receiving final approval will be refused.

Overnight Travel

-    Sales Representatives will focus their activity on their immediate
     metropolitan area. Any overnight travel is an exception, must be
     pre-approved by J. Ledesma and will be covered separately (not offset
     against the Sales Representatives $1500 budget).

-    Guidelines. Destination is more than 2.5 hours drive time from
     representative's location. Hotel accommodation is modest (under $120/night
     total). A per diem expense of up to $30/day will be provided with
     appropriate receipts. Outbound meal expenses will cover lunch and dinner,
     inbound will cover breakfast and lunch.

ADDITIONAL EXPENSE BUDGET (DISCRETIONARY)

Extraordinary Expenses.

-    J.Ledesma can request additional Special Program Funds for individual
     Territories up to a $1750 per Territory limit during the 120day launch
     period. Special Program Funds can be

<PAGE>

     considered for programs where reasonable costs would exceed the $375 per
     month guideline (e.g. speaker programs, roundtable dinners).

-    Sales Representative must submit a proposal to J.Ledesma a minimum of 10
     working days prior to the program outlining (1) business plan for program
     (2) invitees (3) projected impact on sales (4) estimate of costs.

-    J.Ledesma will forward any approved proposals to J.Freeman for final
     approval of funding at a minimum of 5 working days prior to proposed date.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]